<DOC>
	<DOCNO>NCT02565641</DOCNO>
	<brief_summary>This study evaluate efficacy safety oral capecitabine plus intravenous ( IV ) gemcitabine participant locally advance metastatic pancreatic cancer . The anticipated time study treatment 3 12 month , target sample size 56 individual .</brief_summary>
	<brief_title>A Study Capecitabine ( Xeloda ) Participants With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult participant 18 75 year age Locally advance metastatic pancreatic cancer Prior chemotherapy pancreatic cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>